179 related articles for article (PubMed ID: 24813344)
21. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
[TBL] [Abstract][Full Text] [Related]
22. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
23. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
24. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b).
Chin JL; Al-Zahrani AA; Autran-Gomez AM; Williams AK; Bauman G
J Urol; 2012 Oct; 188(4):1170-5. PubMed ID: 22901586
[TBL] [Abstract][Full Text] [Related]
25. Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation.
Ellis DS; Manny TB; Rewcastle JC
Urology; 2007 Feb; 69(2):306-10. PubMed ID: 17320669
[TBL] [Abstract][Full Text] [Related]
26. Cryosurgical ablation of the prostate: high risk patient outcomes.
Prepelica KL; Okeke Z; Murphy A; Katz AE
Cancer; 2005 Apr; 103(8):1625-30. PubMed ID: 15747374
[TBL] [Abstract][Full Text] [Related]
27. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
28. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
29. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
30. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
31. Only carefully selected patients may have a beneficial effect of salvage cryoablation in recurrent prostate cancer after radiotherapy.
Elkjær MC; Borre M
Dan Med J; 2013 Dec; 60(12):A4756. PubMed ID: 24355453
[TBL] [Abstract][Full Text] [Related]
32. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer.
Lambert EH; Bolte K; Masson P; Katz AE
Urology; 2007 Jun; 69(6):1117-20. PubMed ID: 17572198
[TBL] [Abstract][Full Text] [Related]
33. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
34. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
[TBL] [Abstract][Full Text] [Related]
35. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
Tollefson MK; Blute ML; Rangel LJ; Karnes RJ; Frank I
J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
[TBL] [Abstract][Full Text] [Related]
36. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry.
Li YH; Elshafei A; Agarwal G; Ruckle H; Powsang J; Jones JS
Prostate; 2015 Jan; 75(1):1-7. PubMed ID: 25283814
[TBL] [Abstract][Full Text] [Related]
37. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
[TBL] [Abstract][Full Text] [Related]
38. Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.
Aminsharifi A; Jibara G; Tsivian E; Tsivian M; Elshafei A; Polascik TJ
Clin Genitourin Cancer; 2019 Aug; 17(4):e831-e836. PubMed ID: 31213413
[TBL] [Abstract][Full Text] [Related]
39. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
40. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System.
Safavy S; Jabaji RB; Lu SM; Slezak JM; Cosmatos HA; Williams SG; Finley DS
Perm J; 2019; 23():. PubMed ID: 31050644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
